{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:11:27Z","timestamp":1793945487576,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.msard.2023.104498","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T19:18:43Z","timestamp":1672687123000},"page":"104498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"70","author":[{"given":"Alexander D.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatum M.","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy W.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6499-1523","authenticated-orcid":false,"given":"Darin T.","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104498_bib0001","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21307\/ane-2020-023","article-title":"Neuromyelitis optica spectrum disorder: an overview","volume":"80","author":"Ramakrishnan","year":"2020","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"key":"10.1016\/j.msard.2023.104498_bib0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104498_bib0003","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104498_bib0004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1191\/1352458505ms1200cr","article-title":"Neuromyelitis optica with hypothalamic involvement","volume":"11","author":"Poppe","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104498_bib0005","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458511404917","article-title":"Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder","volume":"17","author":"Kim","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104498_bib0006","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104498_bib0007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/WNO.0000000000000396","article-title":"Finding NMO: the evolving diagnostic criteria of neuromyelitis optica","volume":"36","author":"Bennett","year":"2016","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.msard.2023.104498_bib0008","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2023.104498_bib0009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2023.104498_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jim-2019-001126","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.msard.2023.104498_bib0011","first-page":"263","article-title":"Inflammatory demyelinating diseases of the central nervous system","volume":"145","author":"H\u00f6ftberger","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.msard.2023.104498_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci12070885","article-title":"NMOSD-diagnostic dilemmas leading towards final diagnosis","volume":"12","author":"Szewczyk","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2023.104498_bib0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104498_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101452","article-title":"Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases","volume":"37","author":"Wildner","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104498_bib0015","first-page":"1","article-title":"Acute disseminated encephalomyelitis: current perspectives","volume":"7, 1-15","author":"Paolilo","year":"2020","journal-title":"Children (Basel)"},{"key":"10.1016\/j.msard.2023.104498_bib0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ncl.2020.09.003","article-title":"Advances in the treatment of neuromyelitis optica spectrum disorder","volume":"39","author":"Wallach","year":"2021","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2023.104498_bib0017","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104498_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102538","article-title":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","volume":"46","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104498_bib0019","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104498_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102975","article-title":"Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation","volume":"52","author":"Bonnan","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104498_bib0021","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1212\/NXI.0000000000000363","article-title":"Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS","volume":"4","author":"Gahlen","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104498_bib0022","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2023.104498_bib0023","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104498_bib0025","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104498_bib0026","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104498_bib0027","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/s11606-019-05366-z","article-title":"Patient outcomes following interhospital care fragmentation: a systematic review","volume":"35","author":"Snow","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.msard.2023.104498_bib0028","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/jamaneurol.2013.6277","article-title":"Transverse myelitis associated with an itchy rash and hyperCKemia: neuromyelitis optica associated with dermatitis herpetiformis","volume":"71","author":"Iyer","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104498_bib0029","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2014.07.016","article-title":"Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder","volume":"278","author":"Delman","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.104498_bib0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/jim-2016-000339","article-title":"Update on disease-modifying therapies for multiple sclerosis","volume":"65","author":"Vargas","year":"2017","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.msard.2023.104498_bib0031","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/BOR.0000000000000603","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"31","author":"Romeo","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.msard.2023.104498_bib0024","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/jon.13059","article-title":"Dorsal medulla surface texture: differentiating neuromyelitis optica spectrum disorder from multiple sclerosis","volume":"32","author":"Okuda","year":"2022","journal-title":"J. Neuroimaging"},{"key":"10.1016\/j.msard.2023.104498_bib0032","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2377-12-95","article-title":"Diez-Tejedor E. TH1\/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab","volume":"12","author":"Oreja-Guevara","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2023.104498_bib0033","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/cns.12774","article-title":"Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders","volume":"24","author":"Zhang","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.msard.2023.104498_bib0034","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1212\/WNL.0000000000007746","article-title":"Epidemiology of NMOSD in Sweden from 1987 to 2013: a nationwide population-based study","volume":"93","author":"Jonsson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104498_bib0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels","volume":"9","author":"Kim","year":"2013","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2023.104498_bib0036","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"Waters","year":"2008","journal-title":"Arch. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:06:46Z","timestamp":1761901606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":36,"alternative-id":["S2211034823000020"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104498","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104498"}}